- Home
- ESNT vs CANF Comparison
ESNT vs CANF Comparison
Compare ESNT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESNT
- CANF
- Stock Information
- Founded
- ESNT 2008
- CANF 1994
- Country
- ESNT Bermuda
- CANF Israel
- Employees
- ESNT N/A
- CANF N/A
- Industry
- ESNT Property-Casualty Insurers
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ESNT Finance
- CANF Health Care
- Exchange
- ESNT Nasdaq
- CANF Nasdaq
- Market Cap
- ESNT N/A
- CANF 7.9M
- IPO Year
- ESNT 2013
- CANF N/A
- Fundamental
- Price
- ESNT $55.08
- CANF $1.20
- Analyst Decision
- ESNT Buy
- CANF Strong Buy
- Analyst Count
- ESNT 7
- CANF 2
- Target Price
- ESNT $61.71
- CANF $14.00
- AVG Volume (30 Days)
- ESNT 888.8K
- CANF 413.8K
- Earning Date
- ESNT 05-02-2025
- CANF 04-29-2025
- Dividend Yield
- ESNT 2.25%
- CANF N/A
- EPS Growth
- ESNT 5.38
- CANF N/A
- EPS
- ESNT 6.85
- CANF N/A
- Revenue
- ESNT $1,242,904,000.00
- CANF $674,000.00
- Revenue This Year
- ESNT $4.19
- CANF $461.72
- Revenue Next Year
- ESNT $4.79
- CANF N/A
- P/E Ratio
- ESNT $8.04
- CANF N/A
- Revenue Growth
- ESNT 12.00
- CANF N/A
- 52 Week Low
- ESNT $51.61
- CANF $1.22
- 52 Week High
- ESNT $65.33
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- ESNT 47.14
- CANF 37.12
- Support Level
- ESNT $54.36
- CANF $1.22
- Resistance Level
- ESNT $56.58
- CANF $1.82
- Average True Range (ATR)
- ESNT 1.88
- CANF 0.13
- MACD
- ESNT -0.07
- CANF -0.02
- Stochastic Oscillator
- ESNT 48.40
- CANF 3.13
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).